Stryker (SYK)
(Delayed Data from NYSE)
$341.35 USD
-7.32 (-2.10%)
Updated Jun 20, 2024 04:00 PM ET
After-Market: $341.24 -0.11 (-0.03%) 7:42 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Stryker (SYK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$377.52 | $406.00 | $345.00 | 8.27% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Stryker comes to $377.52. The forecasts range from a low of $345.00 to a high of $406.00. The average price target represents an increase of 8.27% from the last closing price of $348.67.
Analyst Price Targets (23)
Broker Rating
Stryker currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 1.62 a month ago based on 26 recommendations.
Of the 27 recommendations deriving the current ABR, 17 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 62.96% and 7.41% of all recommendations. A month ago, Strong Buy made up 65.38%, while Buy represented 7.69%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SYK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 17 | 17 | 17 | 16 |
Buy | 2 | 2 | 2 | 1 | 1 |
Hold | 8 | 8 | 7 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.62 | 1.54 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Hold |
5/22/2024 | Needham & Company | Michael Matson | Hold | Moderate Buy |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/1/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
5/1/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
5/1/2024 | Roth Capital Partners | Jason Wittes | Strong Buy | Strong Buy |
5/1/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/1/2024 | UBS | Danielle Antalffy | Hold | Hold |
5/1/2024 | JMP Securities | David L Turkaly | Not Available | Hold |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
5/1/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
5/1/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/15/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/4/2024 | Evercore Partners | Vijay Kumar | Not Available | Strong Buy |
4/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
3/15/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
2/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/31/2024 | Canaccord Genuity | Caitlin Cronin | Not Available | Strong Buy |
12/1/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 27 |
Average Target Price | $377.52 |
LT Growth Rate | 10.60% |
Industry | Medical - Products |
Industry Rank by ABR | 148 of 252 |
Current Quarter EPS Est: | 2.79 |